Grant: Operating Grant: COVID-19 - Therapeutics
University of Alberta
$675,000.00
Development and Evaluation of SARS-CoV-2 RNA Polymerase Inhibitors
FY 2019-20
Summary
Coronaviruses (CoV) can cause severe human respiratory diseases, which is documented by three major outbreaks over the past 17 years: SARS-CoV in 2003, MERS-CoV in 2012, and currently SARS-CoV-2. In response to the current COVID-19 outbreak caused by SARS-CoV-2, we propose to develop novel tools to discover, develop and evaluate inhibitors of the viral polymerase. The polymerase is an enzyme that is essentially required for the propagation of SARS-CoV-2, which makes it an attractive target for therapeutic intervention strategies.
Department
Program
Operating Grant: COVID-19 - Therapeutics
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
422709
Name
Götte Matthias
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canadian 2019 Novel Coronavirus (2019-nCoV) Rapid Research
Projecttitle
Development and Evaluation of SARS-CoV-2 RNA Polymerase Inhibitors
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$675,000
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 - Therapeutics
Keyworddelim
Biomedical Research: Therapeutics
Abstract
Coronaviruses (CoV) can cause severe human respiratory diseases, which is documented by three major outbreaks over the past 17 years: SARS-CoV in 2003, MERS-CoV in 2012, and currently SARS-CoV-2. In response to the current COVID-19 outbreak caused by SARS-CoV-2, we propose to develop novel tools to discover, develop and evaluate inhibitors of the viral polymerase. The polymerase is an enzyme that is essentially required for the propagation of SARS-CoV-2, which makes it an attractive target for therapeutic intervention strategies.
Competitiondate
202002
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Götte, Matthias
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $675,000~ $0~
